相似化合物
2452342-44-6 22591-21-5 616-27-3欧盟法规
ECHA物质C&L通报REACH预注册上下游产品
CAS号75-97-8 频那酮 | CAS号17510-46-2 (1-叔丁基乙烯氧基)三甲基硅烷 | CAS号112449-69-1 pinacoyl (4-met... | CAS号76955-39-0 2-tert-Butyl-2-... | CAS号36402-36-5 (1-dichlorometh... | CAS号83759-13-1 1-chloro-3,3-di... | CAS号83759-14-2 (Z)-1-chloro-3,... | CAS号30263-69-5 1,1-dichloro-3,... | CAS号27843-27-2 1-Butene,2-chlo... | CAS号917-92-0 3,3-二甲基-1-丁炔 | CAS号75-97-8 频那酮 | CAS号55107-14-7 新戊酰基乙酸甲酯 | CAS号144536-58-3 2-(3,3-dimethyl... | CAS号345627-80-7 SNS-032 (BMS-387032) | CAS号22591-21-5 1,1-二氯频哪酮 | CAS号56658-35-6 2-(3,3-二甲基-2-氧代... | CAS号75-66-1 叔丁基硫醇 | CAS号58905-32-1 3,3-二甲基-1-(1H-1... | CAS号59997-51-2 新戊酰基乙腈频哪酮置于氯体系中,化学反应生成一氯频呐酮
参考文献:α-卤代酮亲核取代的立体化学和空间效应
标题:α-卤代酮亲核取代的立体化学和空间效应
摘要:α-卤代酮与乙酸根和叠氮离子的双分子取代反应对空间位阻非常不敏感.1-溴-4,4-二甲基-2-戊酮(溴甲基新戊基酮)的反应性仅略低于溴丙酮,尽管前者中的羰基是新戊基的.结果根据正常的 Sn2 过渡态进行解释,不涉及进入和离开基团与羰基功能(共轭)的 π 轨道的特殊排列或亲核试剂与羰基碳(桥接)之间的共价相互作用以进行构象反应-Ally-移动系统.另一方面,构象固定系统可能会受到这些因素的影响.在与乙酸盐的 Sn2 反应中,反式,-2-氯-4-叔丁基环己酮的反应性比顺式异构体高 61 倍.
Doi:10.1139/v73-137
海关参考信息
- 2912110000-甲醛
2912120000-乙醛
2914110000-丙酮
2914120000-丁酮 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-4460793-A
优先权日:1980-12-30
标 题:Preparation of monochloromethyl ketones
发明人:JAUTELAT MANFRED; ARLT DIETER; JAEGER GERHARD
权利人:BAYER AG
摘要:A process for the production of a monochloromethyl ketone of the formula in which R1, R2 and R3 each independently is a hydrogen atom or an optionally substituted alkyl, alkenyl, alkinyl or aryl radical, or R1 and R2 together with the carbon atom to which they are attached form an optionally substituted carbocyclic ring, comprising reacting a 1,1-dichloroalkene of the formula with a phenolate of the formula in which R4 each independently is a halogen atom, a nitro group, or an optionally substituted alkyl, alkoxy or aryl radical, n is 0, 1, 2 or 3, and M is one equivalent of an alkali metal ion or alkaline earth metal ion, thereby to obtain a phenyl ether intermediate, and then subjecting the phenyl ether intermediate to an acid hydrolysis. The products are useful as intermediates in the synthesis of fungicides.
专利号:US-2005192265-A1
优先权日:2003-03-20
标 题:Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
发明人:THOMPSON RICHARD C; WILKIE STEPHEN; STACK DOUGLAS R; VANMETER ELDON E; SHI QING; BRITTON THOMAS C; AUDIA JAMES E; REEL JON K; MABRY THOMAS E; DRESSMAN BRUCE A; CWI CYNTHIA L; HENRY STEVEN S; MCDANIEL STACEY L; STUCKY RUSSELL D; PORTER WARREN J
摘要:Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions that include a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
专利号:WO-9967219-A1
优先权日:1998-06-22
标 题:Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
发明人:AUDIA JAMES E; PORTER WARREN J; THOMPSON RICHARD C; WILKIE STEPHEN C; STACK DOUGLAS R; SHI QING
权利人:ELAN PHARM INC; LILLY CO ELI; AUDIA JAMES E; PORTER WARREN J; THOMPSON RICHARD C; WILKIE STEPHEN C; STACK DOUGLAS R; SHI QING
摘要:Compounds of formula (I), wherein W is a cyclic group of the type (2); (3); Y is represented by the formula (II); these compounds inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
专利号:WO-9966934-A1
优先权日:1998-06-22
标 题 :CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
发明人:AUDIA JAMES E; DRESSMAN BRUCE A; SHI QING
权利人:ELAN PHARM INC; LILLY CO ELI; AUDIA JAMES E; DRESSMAN BRUCE A; SHI QING
摘要:Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
专利号:US-6774125-B2
优先权日:1998-06-22
标 题:Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
发明人:AUDIA JAMES E; THOMPSON RICHARD C; WILKIE STEPHEN C; BRITTON THOMAS C; PORTER WARREN J; HUFFMAN GEORGE W; LATIMER LEE H
权利人:ELAN PHARM INC; LILLY CO ELI
摘要:Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
专利号:US-6509331-B1
优先权日:1998-06-22
标题:Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
发明人:AUDIA JAMES E; THOMPSON RICHARD C; WILKIE STEPHEN C; BRITTON THOMAS C; PORTER WARREN J; HUFFMAN GEORGE W; LATIMER LEE H
权利人:ELAN PHARM INC; LILLY CO ELI
摘要:Disclosed are compounds which inhibit beta-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.